Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation

About this update from Kairos Pharma, Ltd.

Company selected as an Emerald honoree for Innovator of Biotech Solutions LOS ANGELES, April 15, 2026--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that it has been named a winner of the 2026 Pinnacle Awards for Healthcare, being selected as an Emerald honoree for Innovator of Biotech Solutions for addressing cancer drug resistance. Kairos Pharma was recognized for its differentiated approach to targeting the biological mechanisms that allow tumors to evade treatment. Rather than developing standalone therapies, Kairos is advancing resistance-modulating treatments designed to restore and extend the effectiveness of existing cancer therapies. At the center of this strategy is ENV-105 (carotuximab), an investigational neutralizing antibody designed to inhibit pathways involved in cancer stem cells and tumor resistance. ENV-105 is being developed in combination with standard-of-care therapies to improve durability of response across multiple indications. "Receiving this Pinnacle Award is validation of our commitment to tackling one of the most complex challenges in cancer care and drug development," said Kairos Pharma Chief Executive Officer Dr. John Yu. "Our focus is not just on treating tumors, but on preventing the biological adaptations that allow them to survive and progress. We owe it to patients facing treatment-resistant disease to not just throw out initially effective treatments when the cancer becomes resistant but to focus on making effective treatments last longer." The Pinnacle Awards is an esteemed annual awards program dedicated to recognizing and celebrating outstanding achievements across various industries. Its mission is to honor companies, products, and individuals that have demonstrated exceptional innovation, creativity, and impact in their fields. Each year, nominees are evaluated by industry experts, media professionals, and consultants who ensure that only the most deserving candidates receive recognition. About Kairos Pharma, Ltd. Based in Los Angeles, California, Kairos Pharma Ltd. (NYSE American: KAPA) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Kairos Pharma’s lead candidate, ENV-105, is an antibody that targe...

View stock analysis, news, and events for Kairos Pharma, Ltd.